BLLN — BillionToOne, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

137.32

-1.28-0.92%

Overview Short InterestFilings

BLLNQT76BillionToOne, Inc.·NASDAQ

Overview Short InterestFilings

137.32-0.92%

Loading chart...

Screen all →

TWST+10.39%$101.06 SHC+0.73%$17.99 RDNT+4.74%$66.80 QGEN+2.25%$42.33 VCYT-3.17%$44.85 CRL-0.71%$230.87 ICLR-3.15%$158.41 RVTY+2.40%$115.22

Snapshot

Index	-	P/E	-	EPS (ttm)	0.51	Insider Own	-	Shs Outstand	46.00M	Perf Week	9.93%

Market Cap	6.37B	Forward P/E	114.87	EPS next Y	1.21	Insider Trans	-	Shs Float	5.46M	Perf Month	13.30%

Enterprise Value	5.98B	PEG	0.05	EPS next Q	0.07	Inst Own	-	Short Float	5.23%	Perf Quarter	84.68%

Income	25.50M	P/S	17.98	EPS this Y	230.60%	Inst Trans	-	Short Ratio	3.36	Perf Half Y	70.67%

Sales	354.54M	P/B	12.59	EPS next Y	23.19%	ROA	3.60%	Short Interest	2.41M	Perf YTD	69.35%

Book/sh	-	P/C	175.78	EPS next 5Y	12.70%	ROE	7.55%	52W High	138.92 -1.15%	Perf Year	-

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	5.43%	52W Low	61.39 123.69%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	146.36	Sales past 3/5Y	-	Gross Margin	70.40%	Volatility	6.07% 5.77%	Perf 5Y	-

Dividend TTM	-	EV/Sales	16.87	EPS Y/Y TTM	19.35%	Oper. Margin	10.20%	ATR (14)	7.38	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	10.58	Sales Y/Y TTM	16.34%	Profit Margin	7.11%	RSI (14)	65.98	Recom	2.25

Dividend Gr. 3/5Y	-	Current Ratio	10.92	EPS Q/Q	209.09%	SMA20	7.96%	Beta	1.74	Target Price	127.50

Payout	0.00%	Debt/Eq	0.29	Sales Q/Q	83.05%	SMA50	23.46%	Rel Volume	0.71	Prev Close	138.60

Employees	713	LT Debt/Eq	0.21	Earnings	Oct 06	SMA200	46.46%	Avg Volume	748.60K	Price	137.32

IPO Date	Nov 06, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	981.80% 11.59%	Net Debt/EBITDA	-9.62	Volume	530,876	Change	-0.92%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-29-26	Reiterated	Guggenheim	Buy	$120 → $125
May-07-26	Reiterated	BTIG	Buy	$140 → $130
Mar-05-26	Reiterated	BTIG	Buy	$160 → $140
Jan-06-26	Initiated	Guggenheim	Buy	$120
Dec-01-25	Initiated	BTIG	Buy	$160
Dec-01-25	Initiated	Wells Fargo	Equal Weight	$110
Dec-01-25	Initiated	Stifel	Buy	$145
Dec-01-25	Reiterated	Piper Sandler		$150
Dec-01-25	Reiterated	Jefferies		$117

Latest News

Jul-29-26

Jul-29-2601:09PM

BillionToOne: The Guidance Looks Conservative, The Price Does NotSeekingAlpha

Jul-20-26

Jul-20-2609:00AM

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstarprnewswire.com

Jul-15-26

Jul-15-2608:05AM

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026globenewswire.com

Jul-12-26

Jul-12-2607:56PM

A BillionToOne Insider Sold 801 Shares as Revenue Jumped 84%fool.com

Jul-08-26

Jul-08-2611:57AM

Tom Gardner's Five Stocks for the Long Term: Big Diversification, AI Research, and Cautionfool.com

Jul-02-26

Jul-02-2610:40AM

Are Medical Stocks Lagging BillionToOne, Inc. (BLLN) This Year?zacks.com

Jun-29-26

Jun-29-2601:00PM

BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Studygurufocus.com

Company

BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023
Total Revenue	178	305	153	72
Cost of Goods Sold Incl. D&A	76	97	72	54
Gross Profit	103	208	81	17
Selling, General and Administrative Excl. Other	100	143	91	64
Research and Development	40	49	37	22
Other Operating Expense	0	0	0	1
Operating Income	-39	16	-47	-69
Interest Expense	1	0	2	3
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	5	-8	8	-10
Net Income Before Taxes	-33	8	-42	-83
Income Taxes	0	0	0	0
Consolidated Net Income	-33	7	-42	-83
Net Income From Continuing Operations	-33	7	-42	-83
Net Income	-33	7	-42	-83
EPS (Recurring)	-0.75	0.06	-0.93	-1.85
EPS (Basic, Before Extraordinaries)	-0.75	0.06	-0.93	-1.85
EPS (Diluted)	-0.75	0.06	-0.93	-1.85
EBITDA	-26	20	-27	-73
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	1,284.77	—	—
Price To Sales Ratio	34.72	12.34	—	—
Gross Margin	57.87	68.20	52.94	23.61
Operating Margin	-21.91	5.25	-30.72	-95.83
Net Margin	-18.54	2.30	-27.45	-115.28
Shares Outstanding	45	46	45	45
Market Capitalization	6,179	3,765	—	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.